Showing results (631-640 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|March 1, 2008
Current management and challenges of malignant disease in the CNS in paediatric leukaemiaChing-Hon Pui, Scott C Howard
The Lancet. Oncology|March 1, 2008
Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancerJohan Bussink, Albert J van der Kogel, Johannes H A M Kaanders
The Lancet. Oncology|January 15, 2021
Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trialB C John Cho, Laura Donahoe, Penelope A Bradbury, et al.
The Lancet. Oncology|February 4, 2021
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trialsAnanya Choudhury, Nuria Porta, Emma Hall, et al.
The Lancet. Oncology|February 4, 2021
Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization GroupRenée L Mulder, Anna Font-Gonzalez, Daniel M Green, et al.
The Lancet. Oncology|February 8, 2021
Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based studyAnton Ryzhov, Marilys Corbex, Marion Piñeros, et al.
The Lancet. Oncology|January 24, 2021
Evidence-based benchmarks for use of cancer surgery in high-income countries: a population-based analysisSathira Kasun Perera, Susannah Jacob, Richard Sullivan, et al.
The Lancet. Oncology|December 10, 2016
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyCharles M Rudin, M Catherine Pietanza, Todd M Bauer, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
The Lancet. Oncology|November 14, 2016
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trialJean Y Tang, Mina S Ally, Anita M Chanana, et al.
Pageof 336